Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women

Glucagon-like peptide-1 (GLP-1) medications are delivering unprecedented weight loss results in postmenopausal women, but a new analysis warns that the hormonal and physiological vulnerabilities unique to this population make muscle preservation a central therapeutic priority, according to Maturitas.¹

“Most women, despite proper dietary and lifestyle habits, gain an average of 1.5 pounds per year in midlife (between ages 45 and 65 years) regardless of initial body size, ethnicity, or race,” wrote the U.S. Pharmacist.² “This is a multifactorial process that may include decreasing estrogen levels, sarcopenia (skeletal muscle loss), insulin resistance, and increased central adiposity. These changes may lead to reduced physical activity, sleep disturbances, and dietary changes.”

The decline in estrogen during postmenopause impairs fatty acid oxidation, redistributes fat toward visceral deposits, and accelerates the loss of lean tissue. When semaglutide induces rapid weight loss, clinical reviews indicate that 25% to 40% of the total weight reduction can consist of lean mass, which poses a serious concern for postmenopausal women with lower baseline muscle reserves.^1,3

Furthermore, reduced upper airway muscle tone and central fat accumulation during menopause heighten the risk of obstructive sleep apnea, a condition that frequently coexists with sarcopenia and metabolic dysfunction.¹

Although semaglutide successfully reduces visceral adiposity and improves cardiometabolic risk factors, medical experts emphasize that lean mass changes must be evaluated alongside functional performance metrics such as handgrip strength rather than being measured in isolation.

READ MORE: GLP-1 Therapy Must Prioritize Metabolic Quality Over Weight Loss

Reassuring Clinical Evidence on Muscle Function

Real-world clinical evidence from the prospective SEMALEAN study offers encouraging insights regarding the quality of semaglutide-induced weight loss.^1,4

In a cohort of adults treated with semaglutide at a weekly dose of 2.4 milligrams, an initial decline in lean mass stabilized after 7 months, and handgrip strength improved significantly by over 4 kilograms at 12 months. Consequently, the overall prevalence of sarcopenic obesity dropped from 49% to 33%, demonstrating that functional muscle capacity can be maintained or improved even as overall body fat decreases.⁴

Comprehensive narrative reviews on older women receiving GLP-1 receptor agonists reinforce that combining pharmacological weight loss with lifestyle interventions is vital to optimize body composition. Clinical guidelines recommend progressive resistance training 2 to 3 times per week alongside a targeted protein intake of 1.2 to 1.5 grams per kilogram of body weight daily to overcome anabolic resistance and stimulate muscle protein synthesis.^1-3

Emerging clinical research is also evaluating investigational combination therapies, such as pairing semaglutide with muscle-sparing agents like bimagrumab, which demonstrated greater total weight loss and fat reduction while preserving lean mass.¹

The Evolving Role of Pharmacist Counseling

As accessible health care professionals, pharmacists are uniquely positioned to guide postmenopausal women through long-term peptide therapy and lifestyle modifications. Pharmacists can evaluate patient-specific factors, including dietary protein intake, hydration status, drug-drug interactions, and concurrent prescription medications that might hinder weight loss, such as beta-blockers or psychotropic agents.^2,5

Routine clinical counseling on protein distribution, resistance exercise, and supportive micronutrients such as vitamin D and creatine can help mitigate sarcopenia and reduce fall risks as well.^1-3

Building Long-Term Infrastructure for Patient Care

With GLP-1 therapy shifting care from short-term weight loss toward chronic metabolic and body composition management, health systems must build robust support frameworks beyond simple medication titration.⁵

As chronic peptide prescribing accelerates across menopause clinics and metabolic practices, establishing specialized pharmacist-led care models will be essential to ensure safe, function-oriented health outcomes for aging women.^1,5

“Preserving skeletal muscle mass and function should be considered a central therapeutic target, rather than a secondary outcome of weight loss interventions,” concluded authors of the current study.¹ “Integrating GLP-1 receptor agonists with adequate nutritional strategies and resistance exercise is likely to support healthier and more sustainable weight reduction while helping preserve musculoskeletal health, although evidence among semaglutide-treated postmenopausal women is limited.”

READ MORE: Women’s Health Resource Center

REFERENCES

1. Pereira NRM, Ishikura IA, Tufik S, et al. Semaglutide in postmenopausal women: clinical implications for weight loss, muscle health, and sleep-disordered breathing. Maturitas. September 1, 2026:109129. doi:10.1016/j.maturitas.2026.109129

2. Olavessen-Holt K. Perimenopausal and postmenopausal weight-loss challenges. US Pharmacist. 2025;50(12):41-46. https://www.uspharmacist.com/article/perimenopausal-and-postmenopausal-weightloss-challenges

3. Moscucci F, Baratta F, Pastori D, et al. A narrative review on GLP-1 receptor agonists for obesity in older women: maximizing weight loss while preserving lean mass. Nutrients. 2026;18(4):632. doi:10.3390/nu18040632

4. Alissou M, Demangeat T, Folope V, et al. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. 2025;28(1):112-121. doi:10.1111/dom.70141

5. Vadiee SS. GLP-1s were only the beginning: the growing role of pharmacists in peptide medicine. Pharmacy Times. May 26, 2026. Accessed September 23, 2026. https://www.pharmacytimes.com/view/glp-1s-were-only-the-beginning-the-growing-role-of-pharmacists-in-peptide-medicine